HC Wainwright Issues Optimistic Outlook for GALT Earnings

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimates for Galectin Therapeutics, now projecting earnings of ($0.11) per share, up from the previous estimate of ($0.18).
• Galectin Therapeutics reported Q2 earnings of ($0.12) EPS, surpassing consensus estimates of ($0.16) by $0.04.
• Institutional investors have been actively buying shares, with notable increases by firms such as Jane Street Group LLC and Vivaldi Capital Management LP during the second quarter.

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for Galectin Therapeutics in a report released on Thursday, August 14th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings per share of ($0.11) for the quarter, up from their prior estimate of ($0.18). HC Wainwright currently has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS and FY2027 earnings at ($0.49) EPS.

Separately, Wall Street Zen upgraded Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $6.00.

Galectin Therapeutics Trading Up 1.0%

NASDAQ GALT traded up $0.04 during trading on Monday, hitting $3.94. 62,922 shares of the company's stock were exchanged, compared to its average volume of 409,048. The company has a market cap of $252.40 million, a PE ratio of -6.16 and a beta of 0.82. The stock's 50 day moving average price is $2.90 and its two-hundred day moving average price is $1.92. Galectin Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $4.41.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.04.

Institutional Trading of Galectin Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GALT. Wealth Enhancement Advisory Services LLC boosted its holdings in Galectin Therapeutics by 46.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,510 shares of the company's stock worth $66,000 after acquiring an additional 16,412 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Galectin Therapeutics during the first quarter worth approximately $287,000. Vivaldi Capital Management LP lifted its holdings in shares of Galectin Therapeutics by 89.9% in the 4th quarter. Vivaldi Capital Management LP now owns 45,628 shares of the company's stock worth $56,000 after purchasing an additional 21,596 shares in the last quarter. Barclays PLC grew its position in Galectin Therapeutics by 91.1% in the 4th quarter. Barclays PLC now owns 54,634 shares of the company's stock valued at $71,000 after purchasing an additional 26,047 shares during the period. Finally, Northern Trust Corp increased its stake in Galectin Therapeutics by 4.3% during the 4th quarter. Northern Trust Corp now owns 244,274 shares of the company's stock valued at $315,000 after purchasing an additional 9,994 shares in the last quarter. 11.68% of the stock is owned by institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.